Aspiriant, LLC Arcellx, Inc. Transaction History
Aspiriant, LLC
- $3.38 Billion
- Q4 2025
A detailed history of Aspiriant, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Aspiriant, LLC holds 7,910 shares of ACLX stock, worth $711,741. This represents 0.02% of its overall portfolio holdings.
Number of Shares
7,910Holding current value
$711,741% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
231Shares Held
51.5MCall Options Held
85.4KPut Options Held
113K-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.35MShares$572 Million0.32% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$418 Million12.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.91MShares$352 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$316 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.05MShares$274 Million15.63% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.94B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...